Insights / USE CASE

Label Expansion of a Diabetes Medication using Observational Cohort Study with RWD / RWE

This study explores the use of real-world data and evidence (RWD/E) from observational cohort studies to support label expansion for a diabetes medication.

The study design utilizes real-world data to assess the medication’s effectiveness in a broader patient population, potentially leading to a more detailed understanding of its benefits. This approach offers advantages in terms of cost-efficiency and the findings can be applied to a larger group of people, unlike traditional randomized controlled trials.

Company Overview
A pharmaceutical company (ABC) involved in the development and marketing of Liraglutide


    Make an impact. Make an appointment with us

    Join us and be a part of the change that prioritizes patient well-being and sets new standards in healthcare innovation.